The Incretin Effect: The Study Behind Ozempic

The incretin effect is the extra insulin released when glucose passes through the gut instead of arriving by vein, even when both routes produce the same blood-glucose curve. Human experiments exposed that gut-to-pancreas message in 1964. Decades of hormone and drug research eventually turned one branch of the signal into Ozempic.

What did the 1964 incretin experiment show?

The 1964 experiment showed that swallowing glucose produced a larger, longer insulin response than receiving glucose intravenously. Blood glucose itself could not fully explain the difference. Two research groups reported the finding that year: Henry Elrick and colleagues in The Journal of Clinical Endocrinology & Metabolism, and Neil McIntyre, Christopher Holdsworth, and David Turner in The Lancet.

The Elrick study enrolled ten metabolically healthy adults. Each received 20 grams of glucose by mouth and, on another day, 20 grams by a one-hour intravenous infusion. The blood-glucose patterns were similar, yet oral glucose caused a sustained insulin rise while IV glucose caused a smaller, brief rise. The authors proposed an extra stimulus from the gut or liver.

The independent McIntyre paper reached the same central idea: glucose entering through the digestive tract carries information that glucose delivered directly to the blood does not. Neither team knew the modern cast of hormones yet. The experiment found the phone call before researchers identified the callers.

Why compare oral and IV glucose at the same blood level?

Matching the blood-glucose curve isolates the route of delivery. Glucose directly stimulates pancreatic beta cells to release insulin, so a higher glucose level would create an obvious confounder. When oral and intravenous glucose produce comparable glycemia but oral glucose still produces more insulin, the remaining difference points to signals triggered by the gut.

That is why the clean modern test uses an “isoglycemic” IV infusion: researchers continually adjust the drip to copy the blood-glucose curve produced by a drink. The oral vs IV glucose insulin gap is then calculated from insulin secretion or from C-peptide, a fragment released alongside insulin that helps estimate pancreatic output.

Equal glucose doses and matched blood-glucose levels are not interchangeable. Later matched-curve studies tightened the design beyond the original 20-gram comparison. That detail is usually missing from the incretin effect explained in a single sentence, but it is why the comparison works.

How large is the incretin effect?

The incretin effect often accounts for roughly 50% to 70% of the insulin response after oral glucose in metabolically healthy people, but no single percentage fits every experiment. The glucose dose, sampling period, participants, and choice of insulin versus C-peptide all change the estimate.

A 1986 human study illustrates the problem. Michael Nauck and colleagues compared 50 grams of oral glucose with a matched IV infusion in eight healthy controls and 14 people with type 2 diabetes. In controls, incretin factors accounted for 72.8% ± 6.9% of the measured insulin response but 58.4% ± 7.6% of the C-peptide response. The same experiment shows why the measurement method matters.

The evidence tier here is strong for the core phenomenon: controlled human physiology experiments repeatedly compare two routes in the same or matched participants. The exact fraction is less portable. Treat 50% to 70% as a useful range, not a biological constant stamped on every meal.

What happens to the incretin effect in type 2 diabetes?

The incretin effect is substantially blunted in type 2 diabetes, though the size depends on the same measurement choices. In Nauck’s 1986 comparison, incretin factors contributed 36.0% ± 8.8% of the insulin response in the diabetes group, versus 72.8% in controls. By C-peptide, the estimates were 7.6% ± 14.5% versus 58.4%.

Those numbers do not mean people with type 2 diabetes simply stop making gut hormones. A modern review of incretins and type 2 diabetes reports that GLP-1 and GIP secretion is not consistently lower. The larger problem includes impaired beta-cell responsiveness, especially a weakened response to GIP, while response to externally supplied GLP-1 is partly preserved.

The incretin effect type 2 diabetes connection is therefore a loss of amplification, not proof of one missing hormone. Gut hormone insulin release still involves glucose, receptor signaling, pancreatic capacity, and insulin clearance.

How did the incretin effect lead to Ozempic?

The incretin effect gave drug researchers a target: copy or preserve a gut signal that can strengthen insulin release when glucose is elevated. Researchers later identified two main incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The GLP-1 peptide hub maps the drug family that grew from that work.

Ozempic contains semaglutide, a long-acting GLP-1 analogue. The current DailyMed label identifies Ozempic as a GLP-1 receptor agonist, records initial U.S. approval in 2017, and states that semaglutide raises insulin and lowers glucagon in a glucose-dependent manner. The label was updated in June 2026.

The lineage is real, but it is not a straight arrow from one 1964 test tube to one brand. The original studies did not test GLP-1, semaglutide, weight loss, or Ozempic. They proved that the digestive route changes insulin biology. Read the plain-English incretin definition for the term itself, or how GLP-1 drugs work for the drug mechanism.

What does the experiment prove—and what does it not?

The experiment proves that the gut adds a powerful insulin-amplifying signal beyond blood glucose alone. It does not prove that every effect comes from GLP-1, that more insulin is always better, or that a physiology result establishes a drug’s benefits and risks. Those are separate claims with separate human evidence.

• Human-controlled evidence: oral glucose produces more insulin than isoglycemic IV glucose.
• Hormone evidence: GIP and GLP-1 explain most of that amplification, with their shares varying by setting.
• Type 2 diabetes evidence: the amplification is reduced, not uniformly absent, and the defect is more complicated than low hormone levels.
• Drug evidence: Ozempic stands on its own pharmacology and clinical trials; the 1964 experiment supplied the biological opening, not the finished verdict.

The fairest summary is also the useful one: a small human experiment showed that the intestine behaves like an endocrine organ, not passive plumbing. Ozempic arrived 53 years later, after scientists learned which gut message to copy and how to keep it circulating long enough to become a medicine.